A 62-year-old woman undergoes staging workup for biopsy-proven pancreatic adenocarcinoma of the body. Contrast-enhanced CT shows a 3.5 cm hypodense lesion with no distant metastases. The clinician needs to assess for vascular invasion (superior mesenteric vein and artery involvement) and distant lymph node metastases to determine resectability. Which investigation is most appropriate for detailed vascular assessment and staging?

Explanation

## Staging Investigation for Pancreatic Cancer Vascular Involvement **Key Point:** Multidetector CT (MDCT) with thin-slice, multiphase imaging (arterial, pancreatic, and portal venous phases) is the gold standard for assessing vascular invasion and determining resectability in pancreatic cancer. ### Rationale for MDCT as Gold Standard 1. **Vascular assessment**: Thin-slice acquisition (≤1 mm) with multiplanar reconstruction allows precise evaluation of tumor-vessel relationships 2. **Resectability criteria**: Determines whether SMV/SMA/portal vein involvement is present (unresectable) or borderline resectable 3. **Metastatic staging**: Simultaneously assesses liver, peritoneum, and distant lymph nodes 4. **Reproducibility**: Objective, operator-independent imaging modality 5. **Availability**: Widely accessible; standard staging imaging in most centers ### Imaging Phases and Their Role | Phase | Timing | Purpose | |---|---|---| | **Arterial** | 20–35 sec | Assess hepatic artery and SMA involvement | | **Pancreatic** | 35–50 sec | Best visualization of pancreatic parenchyma and tumor | | **Portal venous** | 60–70 sec | Assess SMV/portal vein involvement; liver metastases | | **Delayed** | 3–5 min | Assess peritoneal involvement; washout patterns | ### Comparison of Staging Modalities | Investigation | Vascular Assessment | Metastatic Detection | Resectability | Limitation | |---|---|---|---|---| | **MDCT (multiphase)** | Excellent | Excellent | Gold standard | Radiation; contrast allergy | | **PET-CT** | Poor | Good (distant mets) | Not for local staging | Low sensitivity for small nodes; not for vascular detail | | **EUS + Doppler** | Moderate | Poor (limited field) | Limited | Operator-dependent; cannot assess distant disease | | **Diagnostic laparoscopy** | Not applicable | Excellent (peritoneal) | Adjunctive only | Invasive; not routine | **High-Yield:** The CT criteria for **unresectable** pancreatic cancer include: (1) >180° contact with SMV/portal vein, (2) any SMA involvement, (3) celiac axis involvement, (4) distant metastases. MDCT is the investigation that defines these criteria. **Mnemonic:** **SMART** for MDCT phases — **S**lice (thin), **M**ultiphase, **A**rterial/pancreatic/portal, **R**econstruction (multiplanar), **T**umor-vessel relationship. **Clinical Pearl:** In borderline resectable disease, additional imaging (EUS, MRI) may be used to supplement MDCT, but MDCT remains the primary staging modality. [cite:Harrison 21e Ch 297]